References analysis of the Wikipedia article "Neuroleptic malignant syndrome" in the English version

doi.org

Berman, Brian D. (January 2011). "Neuroleptic malignant syndrome: a review for neurohospitalists". The Neurohospitalist. 1 (1). New York City: SAGE Publications: 41–47. doi:10.1177/1941875210386491. PMC 3726098. PMID 23983836.

Strawn JR, Keck PE, Caroff SN (June 2007). "Neuroleptic malignant syndrome". The American Journal of Psychiatry. 164 (6): 870–876. doi:10.1176/ajp.2007.164.6.870. PMID 17541044.

New, Andrea M.; Nelson, Sarah; Leung, Jonathan G. (October 1, 2015). "Psychiatric Emergencies in the Intensive Care Unit". AACN Advanced Critical Care. 26 (4). Aliso Viejo, California: American Association of Critical-Care Nurses: 285–293. doi:10.4037/NCI.0000000000000104. PMID 26484986.

Troller, Julian N.; Chen, Xiaohua; Sachdev, Perminder S. (February 2009). "Neuroleptic malignant syndrome associated with atypical antipsychotic drugs". CNS Drugs. 23 (6). New York City: Springer Nature: 477–92. doi:10.2165/00023210-200923060-00003. PMID 19480467. S2CID 43859486.

Wijdicks, Eelco F.M.; Ropper, Allan H. (26 September 2024). "Neuroleptic Malignant Syndrome". New England Journal of Medicine. 391 (12): 1130–1138. doi:10.1056/NEJMra2404606. PMID 39321364.

Sahin, Aynur; Cicek, Mustafa; Cekic, Ozgen Gonenc; Gunaydin, Mucahit; Aykut, Demet Saglam; Tatli, Ozgur; Karaca, Yunus; Arici, Mualla Aylin (December 2017). "A retrospective analysis of cases with neuroleptic malignant syndrome and an evaluation of risk factors for mortality". Turkish Journal of Emergency Medicine. 17 (4). Ankara, Turkey: Emergency Medicine Association of Turkey: 141–145. doi:10.1016/j.tjem.2017.10.001. PMC 5812912. PMID 29464217.

Khaldi S, Kornreich C, Choubani Z, Gourevitch R (December 2008). "[Neuroleptic malignant syndrome and atypical antipsychotics: a brief review]" [Neuroleptic malignant syndrome and atypical antipsychotics: A brief review]. L'Encephale (in French). 34 (6): 618–624. doi:10.1016/j.encep.2007.11.007. PMID 19081460.

Keyser DL, Rodnitzky RL (April 1991). "Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy". Archives of Internal Medicine. 151 (4): 794–796. doi:10.1001/archinte.151.4.794. PMID 1672810.

Friedman LS, Weinrauch LA, D'Elia JA (August 1987). "Metoclopramide-induced neuroleptic malignant syndrome". Archives of Internal Medicine. 147 (8): 1495–1497. doi:10.1001/archinte.147.8.1495. PMID 3632154.

Buckley PF, Hutchinson M (March 1995). "Neuroleptic malignant syndrome". Journal of Neurology, Neurosurgery, and Psychiatry. 58 (3): 271–273. doi:10.1136/jnnp.58.3.271. PMC 1073359. PMID 7897404.

Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA (October 1989). "Risk factors for neuroleptic malignant syndrome. A case-control study". Archives of General Psychiatry. 46 (10): 914–918. doi:10.1001/archpsyc.1989.01810100056011. PMID 2572206.

Velamoor VR (July 1998). "Neuroleptic malignant syndrome. Recognition, prevention and management". Drug Safety. 19 (1): 73–82. doi:10.2165/00002018-199819010-00006. PMID 9673859. S2CID 23303714.

Otani K, Horiuchi M, Kondo T, Kaneko S, Fukushima Y (June 1991). "Is the predisposition to neuroleptic malignant syndrome genetically transmitted?". The British Journal of Psychiatry. 158 (6): 850–853. doi:10.1192/bjp.158.6.850. PMID 1678666. S2CID 23185221.

Alexander PJ, Thomas RM, Das A (May 1998). "Is risk of neuroleptic malignant syndrome increased in the postpartum period?". The Journal of Clinical Psychiatry. 59 (5): 254–255. doi:10.4088/JCP.v59n0509a. PMID 9632037.

Steinberg M, Lyketsos CG (September 2012). "Atypical antipsychotic use in patients with dementia: managing safety concerns". The American Journal of Psychiatry. 169 (9): 900–906. doi:10.1176/appi.ajp.2012.12030342. PMC 3516138. PMID 22952071.

Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Sano A, et al. (February 2003). "Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 117B (1): 57–60. doi:10.1002/ajmg.b.10025. PMID 12555236. S2CID 44866985.

Kornhuber J, Weller M, Riederer P (1993). "Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis". Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 6 (1): 63–72. doi:10.1007/bf02252624. PMID 8105799. S2CID 45530847.

Chatterjee A (January 2014). "Glutamate-based magnetic resonance spectroscopy in neuroleptic malignant syndrome". Annals of Indian Academy of Neurology. 17 (1): 123–124. doi:10.4103/0972-2327.128579. PMC 3992752. PMID 24753679.

Odagaki Y (January 2009). "Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?". Current Drug Safety. 4 (1): 84–93. CiteSeerX 10.1.1.334.241. doi:10.2174/157488609787354387. PMID 19149529.

Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (April 2004). "Neuroleptic malignant syndrome and atypical antipsychotic drugs". The Journal of Clinical Psychiatry. 65 (4): 464–470. doi:10.4088/JCP.v65n0403. PMID 15119907. S2CID 32752143.

Hasan S, Buckley P (August 1998). "Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique". The American Journal of Psychiatry. 155 (8): 1113–1116. doi:10.1176/ajp.155.8.1113. PMID 9699705.

Gurrera RJ (February 1999). "Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome". The American Journal of Psychiatry. 156 (2): 169–180. doi:10.1176/ajp.156.2.169. PMID 9989551. S2CID 31276121.

Gurrera RJ (2002). "Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia?". Clinical Neuropharmacology. 25 (4): 183–193. doi:10.1097/00002826-200207000-00001. PMID 12151905. S2CID 29010904.

Northoff G (December 2002). "Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology". Journal of Neural Transmission. 109 (12): 1453–1467. CiteSeerX 10.1.1.464.9266. doi:10.1007/s00702-002-0762-z. PMID 12486486. S2CID 12971112.

Sachdev PS (June 2005). "A rating scale for neuroleptic malignant syndrome". Psychiatry Research. 135 (3): 249–256. doi:10.1016/j.psychres.2005.05.003. hdl:1959.4/unsworks_46263. PMID 15996751. S2CID 25728796.

Ahuja N, Cole AJ (2009). "Hyperthermia syndromes in psychiatry". Advances in Psychiatric Treatment. 15 (3): 181–91. doi:10.1192/apt.bp.107.005090.

Guinart, Daniel; Taipale, Heidi; Rubio, Jose M; Tanskanen, Antti; Correll, Christoph U; Tiihonen, Jari; Kane, John M (21 October 2021). "Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort". Schizophrenia Bulletin. 47 (6): 1621–1630. doi:10.1093/schbul/sbab062. PMC 8530388. PMID 34013325.

Pelonero AL, Levenson JL, Pandurangi AK (September 1998). "Neuroleptic malignant syndrome: a review". Psychiatric Services. 49 (9): 1163–1172. doi:10.1176/ps.49.9.1163. PMID 9735957.

Hernández JL, Palacios-Araus L, Echevarría S, Herrán A, Campo JF, Riancho JA (December 1997). "Neuroleptic malignant syndrome in the acquired immunodeficiency syndrome". Postgraduate Medical Journal. 73 (866): 779–784. doi:10.1136/pgmj.73.866.779. PMC 2431511. PMID 9497946.

mhmedical.com

accessmedicine.mhmedical.com

Papadakis MA, McPhee SJ (2023). "Neuroleptic malignant syndrome.". Quick Medical Diagnosis & Treatment. McGraw Hill.

Miller CS, Wiese JG (2017). "Hyperthermia and fever.". In McKean SC, Ross JJ, Dressler DD, Scheurer DB (eds.). Principles and Practice of Hospital Medicine (2nd ed.). McGraw Hill. ISBN 978-0-07-184313-3.

Huppert LA, Dyster TG (2021). "Key medications & interventions in psychiatry.". Huppert's Notes: Pathophysiology and Clinical Pearls for Internal Medicine. McGraw Hill. ISBN 978-1-260-47007-9.

Butterworth IV JF, Mackey DC, Wasnick JD (2022). "Thermoregulation, hypothermia, & malignant hyperthermia.". Morgan & Mikhail's Clinical Anesthesiology (7th ed.). McGraw Hill. ISBN 978-1-260-47379-7.

Stringer JL, ed. (2017). "Antipsychotics or neuroleptics.". Basic Concepts in Pharmacology: What You Need to Know for Each Drug Class (5th ed.). McGraw Hill. ISBN 978-1-259-86107-9.

Yandle G, deBoisblanc BP (2014). "Persistent fever". In Hall JB, Schmidt GA, Kress JP (eds.). Principles of Critical Care (4th ed.). McGraw Hill. ISBN 978-0-07-173881-1.

nih.gov

pubmed.ncbi.nlm.nih.gov

Strawn JR, Keck PE, Caroff SN (June 2007). "Neuroleptic malignant syndrome". The American Journal of Psychiatry. 164 (6): 870–876. doi:10.1176/ajp.2007.164.6.870. PMID 17541044.

Wijdicks, Eelco F.M.; Ropper, Allan H. (26 September 2024). "Neuroleptic Malignant Syndrome". New England Journal of Medicine. 391 (12): 1130–1138. doi:10.1056/NEJMra2404606. PMID 39321364.

Simon LV, Hashmi MF, Callahan AL (August 2022). "Neuroleptic Malignant Syndrome.". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 29489248.

Buckley PF, Hutchinson M (March 1995). "Neuroleptic malignant syndrome". Journal of Neurology, Neurosurgery, and Psychiatry. 58 (3): 271–273. doi:10.1136/jnnp.58.3.271. PMC 1073359. PMID 7897404.

Velamoor VR (July 1998). "Neuroleptic malignant syndrome. Recognition, prevention and management". Drug Safety. 19 (1): 73–82. doi:10.2165/00002018-199819010-00006. PMID 9673859. S2CID 23303714.

Latham J, Campbell D, Nichols W, Mott T (August 2008). "Clinical inquiries. How much can exercise raise creatine kinase level--and does it matter?". The Journal of Family Practice. 57 (8): 545–547. PMID 18687233. Archived from the original on 2016-06-01.

Christensen V, Glenthøj BY (January 2001). "[Malignant neuroleptic syndrome or serotonergic syndrome]". Ugeskrift for Laeger. 163 (3): 301–302. PMID 11219110.

Birmes P, Coppin D, Schmitt L, Lauque D (May 2003). "Serotonin syndrome: a brief review". CMAJ. 168 (11): 1439–1442. PMC 155963. PMID 12771076.

Dhib-Jalbut S, Hesselbrock R, Mouradian MM, Means ED (February 1987). "Bromocriptine treatment of neuroleptic malignant syndrome". The Journal of Clinical Psychiatry. 48 (2): 69–73. PMID 3804991.

Pelonero AL, Levenson JL, Pandurangi AK (September 1998). "Neuroleptic malignant syndrome: a review". Psychiatric Services. 49 (9): 1163–1172. doi:10.1176/ps.49.9.1163. PMID 9735957.

ncbi.nlm.nih.gov

ninds.nih.gov

"Neuroleptic Malignant Syndrome Information Page". Bethesda, Maryland: National Institute of Neurological Disorders and Stroke. Archived from the original on 4 July 2017. Retrieved 1 July 2017.

psu.edu

citeseerx.ist.psu.edu

semanticscholar.org

api.semanticscholar.org

Velamoor VR (July 1998). "Neuroleptic malignant syndrome. Recognition, prevention and management". Drug Safety. 19 (1): 73–82. doi:10.2165/00002018-199819010-00006. PMID 9673859. S2CID 23303714.

web.archive.org

"Neuroleptic Malignant Syndrome". NORD (National Organization for Rare Disorders). 2004. Archived from the original on 19 February 2017. Retrieved 1 July 2017.

"Neuroleptic Malignant Syndrome Information Page". Bethesda, Maryland: National Institute of Neurological Disorders and Stroke. Archived from the original on 4 July 2017. Retrieved 1 July 2017.

Milbouer S. "Quest for the truth". Nashua Telegraph. Archived from the original on 2007-09-27.

Friedberg JM. "Neuroleptic malignant syndrome". Archived from the original on October 16, 2006. Retrieved 2006-07-03. ^{[self-published source]}

Neuroleptic malignant syndrome (English Wikipedia)

books.google.com

cmaj.ca

doi.org

handle.net

hdl.handle.net

idiom.com

jfponline.com

medscape.com

emedicine.medscape.com

mhmedical.com

accessmedicine.mhmedical.com

nashuatelegraph.com

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

ninds.nih.gov

psu.edu

citeseerx.ist.psu.edu

rarediseases.org

semanticscholar.org

api.semanticscholar.org

tulane.edu

tmedweb.tulane.edu

uptodate.com

web.archive.org